Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NDRA
stocks logo

NDRA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-1.950
-107.74%
--
--
-2.460
+32.26%
--
--
-2.150
+25.73%
Estimates Revision
The market is revising No Change the revenue expectations for ENDRA Life Sciences Inc. (NDRA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 28.81%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+28.81%
In Past 3 Month
Wall Street analysts forecast NDRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NDRA is 38.00 USD with a low forecast of 38.00 USD and a high forecast of 38.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast NDRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NDRA is 38.00 USD with a low forecast of 38.00 USD and a high forecast of 38.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.500
sliders
Low
38.00
Averages
38.00
High
38.00
Current: 5.500
sliders
Low
38.00
Averages
38.00
High
38.00
Ascendiant Capital
Edward Woo
Strong Buy
Maintains
$75 → $50
2025-04-21
Reason
Ascendiant Capital
Edward Woo
Price Target
$75 → $50
2025-04-21
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for ENDRA Life Sciences Inc (NDRA.O) is -0.63, compared to its 5-year average forward P/E of -2.33. For a more detailed relative valuation and DCF analysis to assess ENDRA Life Sciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.33
Current PE
-0.63
Overvalued PE
0.27
Undervalued PE
-4.94

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.54
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.95
Undervalued EV/EBITDA
-2.02

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
30.03
Current PS
0.00
Overvalued PS
100.59
Undervalued PS
-40.54
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
FCF Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

NDRA News & Events

Events Timeline

(ET)
2025-12-04
08:20:00
Endra Life Sciences Reports Significant Results from 2025 Taeus Liver Device Study
select
2025-11-13 (ET)
2025-11-13
09:20:47
Endra Life Sciences Begins Staking HYPE Digital Asset Holdings
select
2025-08-14 (ET)
2025-08-14
16:14:06
Endra Life Sciences reports Q2 EPS ($1.71) vs. (8c) last year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
12-04Newsfilter
ENDRA Launches Low-Cost TAEUS Liver Detection Technology Under $200
  • Technology Validation: ENDRA's TAEUS device demonstrates a 100% PPV and 94% NPV at liver fat fraction thresholds of 12-22%, with an accuracy of 95%, showcasing its potential in clinical decision-making by effectively distinguishing between mild and severe steatosis patients.
  • Cost Advantage: With an anticipated cost of under $200, TAEUS offers a significant reduction compared to the $2,500 MRI-PDFF exams, enabling frequent monitoring every eight weeks, thus lowering the high screening costs associated with drug development.
  • Market Opportunity: As over 50 MASLD/MASH and 250 GLP-1 trials are ongoing globally, TAEUS's high accuracy and low cost position it as an ideal choice for drug developers and payors, significantly reducing overall clinical trial costs.
  • Strategic Pathway: ENDRA plans to engage with the FDA in 2026 to align on clinical decision thresholds in multicenter studies, further advancing TAEUS's market application and regulatory approval.
[object Object]
Preview
8.5
10-13SeekingAlpha
ENDRA Life Sciences Reveals At-Market Private Placement Opportunity of Up to $14.4 Million

  • Private Placement Announcement: ENDRA Life Sciences has secured $4.9 million in commitments for a private placement, involving the sale of 744,340 shares of common stock and warrants for an additional 1.48 million shares.

  • Use of Proceeds and Advisory Board Addition: The company plans to use the majority of the net proceeds to establish its DAT operations and accumulate cryptocurrency, while also adding Jeff Dorman to its Digital Asset Advisory Board.

[object Object]
Preview
4.0
09-22Benzinga
Ascendiant Capital Reaffirms Buy Rating on ENDRA Life Sciences, Adjusts Price Target to $38

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Exclusive Community: Joining Benzinga Pro connects traders with over 10,000 serious market participants and provides access to exclusive stories and insights from Benzinga reporters.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is ENDRA Life Sciences Inc (NDRA) stock price today?

The current price of NDRA is 5.5 USD — it has decreased -7.67 % in the last trading day.

arrow icon

What is ENDRA Life Sciences Inc (NDRA)'s business?

ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.

arrow icon

What is the price predicton of NDRA Stock?

Wall Street analysts forecast NDRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NDRA is 38.00 USD with a low forecast of 38.00 USD and a high forecast of 38.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is ENDRA Life Sciences Inc (NDRA)'s revenue for the last quarter?

ENDRA Life Sciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is ENDRA Life Sciences Inc (NDRA)'s earnings per share (EPS) for the last quarter?

ENDRA Life Sciences Inc. EPS for the last quarter amounts to -2.10 USD, decreased -99.37 % YoY.

arrow icon

What changes have occurred in the market's expectations for ENDRA Life Sciences Inc (NDRA)'s fundamentals?

The market is revising No Change the revenue expectations for ENDRA Life Sciences Inc. (NDRA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 28.81%.
arrow icon

How many employees does ENDRA Life Sciences Inc (NDRA). have?

ENDRA Life Sciences Inc (NDRA) has 21 emplpoyees as of December 05 2025.

arrow icon

What is ENDRA Life Sciences Inc (NDRA) market cap?

Today NDRA has the market capitalization of 6.42M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free